MEDULLOBLASTOMA

This early-phase study tests a personalized cell therapy called B7-H3 CAR T cells in 70 children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a prote…

This early-stage trial tests a combination of a vaccine targeting a common virus (CMV) and an immunotherapy drug (nivolumab) in children and young adults with aggressive brain tumors like diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe and …

This study tests a special proton therapy technique that avoids radiating the growing parts of the spine in children with brain tumors. The goal is to preserve bone marrow and reduce side effects like growth problems. About 38 children and teens will be followed for up to 5 years…

This study tests a thyroid hormone (liothyronine, or L-T3) alone or with standard chemotherapy in 69 children and young adults whose medulloblastoma has returned or worsened. The goal is to see if adding L-T3 makes treatment safer and more effective. Participants receive either L…

This study tests a new approach for people with brain tumors that have not responded to standard treatments. A lab test called pharmacoscopy analyzes a patient's tumor cells to find which drugs might work best for them. The goal is to see if this personalized method is feasible a…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if using the app helps patients feel…

This study looks at how well young children's brains work 2.5 years after treatment for a low-risk type of brain tumor called medulloblastoma. About 96 children under age 5 will receive one of two standard chemotherapy regimens. The goal is to see which treatment better protects …